The UK Biobank Pharma Project publishes early results from its groundbreaking protein research

Olink Proteomics AB

UPPSALA, Sweden, June 21, 2022 (GLOBE NEWSWIRE) – Olink Holding AB (12 months of publication) (Nasdaq: OLK) has introduced {that a} publication describing early outcomes of protein analysis performed by the UK’s Important Pharma Proteins Mission (UKB-PPP) has been Publish it on-line to bioRxiv Prepress server, out there over right here.

The research is entitledGenetic regulation of human plasma protein in 54,306 UK Biobank individualsOlink® Discover 1536 and genome sequencing on 54,306 UK Biobank individuals to gather and analyze information from protein quantitative trait (pQTL) sitemaps for 1,463 proteins figuring out 10,248 main genetic associations, 85% of which haven’t been beforehand reported.

The outcomes of the UKB-PPP publication present an up to date genetic atlas of plasma proteins and supply the scientific group with an open-access protein supply of broad scope and unprecedented depth to assist elucidate the organic mechanisms underlying genetic discoveries. Measuring hundreds of proteins at a inhabitants scale guarantees to enhance our understanding of the mechanisms underlying illness, thus accelerating the event of latest biomarkers and therapeutics. Moreover, the research highlights the strengths of Olink’s Discover assay for pQTL and downstream biodetection, with a excessive proportion, 82% of the proteins examined, after Commonwealth of Unbiased States Associations, proof for extremely particular Olink assays that measure supposed proteins.

“The landmark analysis by UKB-PPP members is a significant early step in harnessing the ability of next-generation proteins mixed with genetic info to enhance human well being,” John Hymer, CEO of Olink. “We’re very grateful that Olink’s Discover platform might be part of this great journey, and we eagerly await the total dataset that will likely be launched to the scientific group by the top of this 12 months.”

The UK Biobank Pharma Mission is a collaboration between Biobank within the UK and 13 biopharmaceutical corporations, and is at the moment conducting one of many world’s largest scientific research of blood protein biomarkers. The UK Biobank is an intensive biomedical database and analysis useful resource containing in-depth genetic and well being info from half 1,000,000 UK individuals. The database is globally accessible to researchers and licensed scientists who conduct important analysis in the most typical and life-threatening ailments. The UKB-PPP goals to allow a greater understanding of illness biology and assist the event of progressive medicine for simpler therapies.

Olink Investor Contact
Jean Medina, CFA
Vice President of Investor Relations and Capital Markets
Cell: +1617802 4157
jan.medina@olink.com

Olink Media Contact
Andrea Brander
Company Communications Supervisor
Cell: +46768775275
andrea.prander@olink.com

About Olink
Olink Holding AB (Nasdaq: OLK) is an organization devoted to accelerating proteins together with the scientific group, throughout a number of illness areas to allow new discoveries and enhance sufferers’ lives. Olink offers a platform of services deployed throughout main biopharmaceutical corporations and main medical and tutorial establishments to deepen understanding of human biology in actual time and advance well being care within the twenty first century by means of highly effective and impactful science. The corporate was based in 2016 and is properly established throughout Europe, North America and Asia. Ulink is headquartered in Uppsala, Sweden. Be taught extra about Olink over right here.

forward-looking statements
This press launch incorporates forward-looking statements which might be based mostly on administration’s beliefs and assumptions and on info at the moment out there to administration. All statements on this launch apart from statements of historic details are forward-looking statements, together with statements relating to our 2022 income projections, our exterior purposes, our capability to develop, market and obtain market acceptance of our present and deliberate services, analysis and improvement efforts, and different issues regarding enterprise methods. Our enterprise, capital use, outcomes of operations and monetary place, and plans and targets for future operations. In some instances, it’s possible you’ll establish forward-looking statements by the phrases “might,” “will,” “might,” “will,” “ought to,” “count on,” “intend,” “plan,” “count on,” “consider.” or “estimate,” “predict,” “mission,” “possible,” “going,” “ongoing,” or damaging of those or different comparable phrases, though not all forward-looking statements include these phrases. These statements contain dangers, uncertainties and different components that might trigger precise outcomes, ranges of exercise, efficiency or achievements to vary materially from the knowledge supplied or included in these forward-looking statements. These dangers, uncertainties and different components are described below the caption “Danger Components” on our Type 20-F (Fee File Quantity 001-40277) and elsewhere in paperwork we file with the Securities and Trade Fee on occasion. We warning you that forward-looking statements are based mostly on a mix of details and components at the moment identified to us and our expectations for the longer term, of which we can’t be sure. In consequence, the forward-looking statements is probably not correct. The forward-looking statements contained on this press launch symbolize our views as of the date of this launch. We don’t undertake to replace any forward-looking statements for any purpose, besides as required by regulation.